(Q45445842)

14 December 2017

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants (English)

1 reference

14 December 2017

1 reference

1 reference

1 reference

1 reference

15

Pierre Van Damme

1 reference

14 December 2017

David Fitzsimons

1

1 reference

14 December 2017

Guido François

2

1 reference

14 December 2017

Andrew Hall

3

1 reference

14 December 2017

Brian McMahon

4

1 reference

14 December 2017

André Meheus

5

1 reference

14 December 2017

Alessandro Zanetti

6

1 reference

14 December 2017

Bernard Duval

7

1 reference

14 December 2017

Wolfgang Jilg

8

1 reference

14 December 2017

Wulf Otto Böcher

9

1 reference

14 December 2017

Sheng-Nan Lu

10

1 reference

14 December 2017

Ulus Akarca

11

1 reference

14 December 2017

Daniel Lavanchy

12

1 reference

14 December 2017

Susan Goldstein

13

1 reference

14 December 2017

Jangu Banatvala

14

1 reference

14 December 2017

language of work or name

English

0 references

publication date

13 April 2005

1 reference

14 December 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 December 2017

23

1 reference

14 December 2017

4158-4166

1 reference

14 December 2017

32

1 reference

We have a cancer vaccine--why don't we use it?

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B vaccination in children: persistence of immunity at 9 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Twelve-year follow-up study of hepatitis B immunization of Senegalese infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B vaccination in high-risk infants: 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Nationwide vaccination: a success story in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Vaccination against hepatitis B: current challenges for Asian countries and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B virus infection in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Chronic hepatitis B virus infection in Asian countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

The Gambia Hepatitis Intervention Study: follow-up of a cohort of children vaccinated against hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Impact of hepatitis B immunisation as part of the EPI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Hepatitis B in Italy: where we are ten years after the introduction of mass vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Seroepidemiology of hepatitis B virus infection in Saudi Arabian children: a baseline survey for mass vaccination against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Integration of hepatitis B vaccine into the expanded program on immunization: The Saudi Arabian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

The serology of chronic hepatitis B infection revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or After HBs vaccination: Stimulation of thein vitroantibody response by interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Persistence of specific antibodies after hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Vaccine-induced escape mutant of hepatitis B virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Current aspects of hepatitis B surface antigen mutants in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

Effect of hepatitis B virus mutants on efficacy of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.017

10.1016/J.VACCINE.2005.03.017

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference